Combination laser and ointment therapy effective in treating vitiligo

September 20, 2004

CHICAGO - Patients with vitiligo, a skin disorder characterized by patches of white, or de-pigmented skin, had better repigmentation of these patches when they were treated with a combination of laser therapy and tacrolimus ointment than patients treated with laser therapy alone, according to an article in the September issue of The Archives of Dermatology, one of the JAMA/Archives journals.

According to the article, vitiligo is a skin pigmentation disorder that affects one percent to two percent of people worldwide. Patients with vitiligo develop white patches on their skin, referred to as "lesions." Recently, the 308-nm (nanometer) excimer laser has been used to treat lesions associated with vitiligo with good results. Additionally, a new topical ointment called tacrolimus has shown promise in treating vitiligo.

Thierry Passeron, M.D., of Hopital de l'Archet, Nice, France, and colleagues investigated the effects of the 308-nm excimer laser in combination with tacrolimus on 14 patients with vitiligo aged 12 to 63 years.

For each patient, four to ten lesions were chosen and treated twice a week with the 308-nm excimer laser for a total of 24 sessions. Topical 0.1 percent tacrolimus ointment was applied twice daily to target lesions for patients in group A (excimer laser plus tacrolimus). Patients in group B received only the laser treatments. Treated lesions were compared with control lesions (that received no treatment) on the opposite side of the body. Forty-three lesions were treated (23 in group A and 20 in group B).

The researchers observed repigmentation in all group A lesions (100 percent) and in 17 (85 percent) of the 20 group B lesions. Repigmentation was not observed in the control lesions.

"A repigmentation rate of 75 percent or more was obtained in 16 (70 percent) of the 23 group A lesions and in 4 (20 percent) of the 20 group B lesions," the authors write. The average number of sessions needed to see an improvement in repigmentation was 10 for group A and 12 for group B.

"The combination of 0.1 percent tacrolimus ointment applied twice daily and 308-nm excimer laser therapy performed twice a week gives excellent results on UV-sensitive and UV-resistant areas. The treatment was well tolerated, and the patients were satisfied," the researchers conclude.

(Arch Dermatol. 2004;140:1065-1069. Available post-embargo at archdermatol.com)
-end-
To contact Thierry Passeron, M.D., e-mail t.passeron@free.fr

For more information, contact JAMA/Archives Media Relations at 312-464-JAMA (5262) or e-mail mediarelations@jama-archives.org.

The JAMA Network Journals

Related Vitiligo Articles from Brightsurf:

Immunotherapy side effect could be a positive sign for kidney cancer patients
An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP).

Henry Ford study demonstrates UV-C light is effective for killing COVID-19 on N95s
Dermatology researchers at Henry Ford Health System, in collaboration with a team at the University of Michigan, have demonstrated that certain N95 respirators tainted with COVID-19 can be effectively and safely decontaminated for reuse using ultraviolet-C light (UV-C), a method commonly utilized for treating rare skin diseases.

Blocking nerve signals to the pancreas halts type 1 diabetes onset in mice
In a new Science Advances study, researchers at La Jolla Institute for Immunology (LJI) report that the nervous system may be driving this patchy cell die-off.

Nanosize device 'uncloaks' cancer cells in mice and reveals them to the immune system
Scientists at Johns Hopkins report they have designed and successfully tested an experimental, super small package able to deliver molecular signals that tag implanted human cancer cells in mice and make them visible for destruction by the animals' immune systems.

Shedding light on the reaction mechanism of PUVA light therapy for skin diseases
Together with their Munich-based colleagues, a team of physical chemists from Heinrich Heine University Düsseldorf (HHU) has clarified which chemical reactions take place during PUVA therapy.

New studies by CU researchers highlight causes of vitiligo
A pair of new journal articles by researchers at the University of Colorado School of Medicine indicate that both genetic and environmental factors play significant roles in the onset of vitiligo, an autoimmune disease that results in the loss of color in blotches of skin.

Topical cream shows promise in treatment of skin pigmentation disease, vitiligo
A nationwide phase II clinical trial, coordinated out of Tufts Medical Center in Boston, has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin pigmentation.

People with benign skin condition willing to trade time, money to cure disorder
People with benign hyperpigmentation (the darkening or increase in the natural color of the skin), are willing to pay (WTP) nearly 14 percent of their monthly income and approximately 90 minutes a day to cure their condition.

Autoimmune diseases are related to each other, some more than others
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.

Yale experts treat severe, disfiguring sarcoidosis with novel therapy
An all-Yale team of researchers successfully treated a patient with disfiguring sarcoidosis, a chronic disease that can affect multiple organs, with a drug approved for rheumatoid arthritis.

Read More: Vitiligo News and Vitiligo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.